Hostname: page-component-77c89778f8-swr86 Total loading time: 0 Render date: 2024-07-18T11:19:56.184Z Has data issue: false hasContentIssue false
  • English
  • Français

AIDS Update: HTLV-III Testing, Immune Globulins and Employees with AIDS

Published online by Cambridge University Press:  02 January 2015

William M. Valenti
William M. Valenti*
Affiliation:
University of Rochester Medical Center, Rochester, New York
*
University of Rochester Medical Center, Box 689, 601 Elmwood Avenue, Rochester, NY 14642
Get access Rights & Permissions [Opens in a new window]

Extract

As we have become experienced in dealing with AIDS, we have learned that early concern over employees who refuse to care for patients with AIDS was merely the tip of the iceberg from the infection control standpoint. During the past 5 years, additional questions and concerns have been raised regarding employee health and AIDS. An interesting body of literature has emerged recently that discusses many of these current employee health issues. Some of these questions have been answered in major communications in The New England Journal of Medicine, the Journal of the American Medical Association, and The Lancet. Many other topics have been covered in short communications in letters to the editor in these same journals and in the CDC's Morbidity and Mortality Weekly Report (MMWR). When taken together, this writing presents a very clear picture of what is happening with AIDS in the health care arena. It is obvious that most of the concerns regarding AIDS in health care settings can be answered by taking a close look at the available epidemiologic data. It is important to remember that the decision-making process related to AIDS is easier if we try to separate the emotional issues surrounding the disease from the scientific data available.

Type
Special Sections
Information
Infection Control & Hospital Epidemiology , Volume 7 , Issue 8 , August 1986 , pp. 427 - 430
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1986

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Ho, DD, Byington, RE, Schooley, RT, et al: Infrequency of isolation of HTLV-III virus from saliva in AIDS. N Engl J Med 1986; 313:1606.Google Scholar
2.McCray, E: Occupational risk of the acquired immunodeficiency syndrome among health care workers. N Engl J Med 1986; 314:1127–1132.CrossRefGoogle ScholarPubMed
3.Stricof, RL, Morse, DL: HTLV-III/LAV seroconversion following a deep intramuscular needlestick injury. N Engl J Med 1986; 314:1115.Google ScholarPubMed
4.Centers for Disease Control: Apparent transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus from a child to a mother providing health care. MMWR 1986; 35:76–79.Google Scholar
5.Centers for Disease Control: Summary: Recommendations for preventing transmission of infection with human T-lymphotropic virus type III/lymphadenopathy-associated virus in the workplace. MMWR 1985; 34:681–695.Google Scholar
6.Centers for Disease Control: Recommendations for preventing transmission of infection with human T-lymphotropic virus type III/lymphadenopathy-associated virus during invasive procedures. MMWR 1986; 35:221–233.Google Scholar
7.Dworsky, ME, Welch, K, Cassady, G, et al: Occupational risk for primary cytomegalovirus infection among pediatric health care workers. N Engl J Med 1983; 309:950–953.CrossRefGoogle ScholarPubMed
8.Martin, LS, McDougal, S, Loskoski, SL: Disinfection and inactivation of the human T lymphotropic virus type III/lymphadenopathy-associated virus. J Infect Dis 1985; 152:400–403.CrossRefGoogle ScholarPubMed
9.Centers for Disease Control: Hepatitis B vaccine: Evidence confirming lack of AIDS transmission. MMWR 1984; 33:685–687.Google Scholar
10.Valenti, WM, Anarella, JP: Survey of hospital personnel on the understanding of the acquired immunodificiency syndrome. Am J Infect Control 1986; 14:60–63.Google Scholar
11.Centers for Disease Control: Safety of therapeutic immune globulin preparations with respect to transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus infection. MMWR 1986; 35:231–233.Google Scholar